Evidence map›Paper›PMID 40100385›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Succinate dehydrogenase deficient renal cell carcinoma frequently expresses GATA3 and L1CAM.

Ankur R Sangoi, Sean R Williamson, Murat Oktay, Anthony J Gill, Kiril Trpkov, Farshid Siadat, Fiona MacLean, Laurence A Galea, Dilek Ertoy Baydar, Caglar Cakir and 14 more

Erratum issuedAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Ankur R SangoiDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0874-8964
Sean R WilliamsonDepartment of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-3898-1460
Murat OktayDepartment of Pathology, Memorial Hospital, Istanbul, Türkiye.ORCID http://orcid.org/0009-0002-7027-1175
Anthony J GillSydney Medical School, University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-9447-1967
Kiril TrpkovDepartment of Pathology and Laboratory Medicine, Alberta Precision Laboratories and University of Calgary, Calgary, AB, Canada.ORCID http://orcid.org/0000-0003-3142-8846
Farshid SiadatDepartment of Pathology and Laboratory Medicine, Alberta Precision Laboratories and University of Calgary, Calgary, AB, Canada.
Fiona MacLeanDouglass Hanly Moir Pathology, Macquarie Park, Australia.ORCID http://orcid.org/0000-0002-6468-2368
Laurence A GaleaDepartment of Pathology, Melbourne Hospital/Sonic Healthcare, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-7968-1846
Dilek Ertoy BaydarDepartment of Pathology, Koc University, Istanbul, Türkiye.ORCID http://orcid.org/0000-0003-0784-8605
Caglar CakirDepartment of Pathology, Cemil Tascioglu Hospital, Istanbul, Türkiye.
Yasemin Yuyucu KarabulutDepartment of Pathology, Mersin University School of Medicine, Mersin, Türkiye.ORCID http://orcid.org/0000-0001-6619-6868
Deniz BaycelebiDepartment of Pathology, Ondokuz Mayis University, Samsun, Türkiye.ORCID http://orcid.org/0000-0002-1660-3629
Ganime CobanDepartment of Pathology, Department of Pathology, Bezmialem University, Istanbul, Türkiye.ORCID http://orcid.org/0000-0002-5779-6797
Banu SarsikDepartment of Pathology, Ege University School of Medicine, Izmir, Türkiye.ORCID http://orcid.org/0000-0003-4775-3942
Busra Yaprak BayrakDepartment of Pathology, Kocaeli University School of Medicine, Kocaeli, Türkiye.
Levente KuthiDepartment of Surgical and Molecular Pathology Center, National Institute of Oncology, Budapest, Hungary.ORCID http://orcid.org/0000-0001-9247-6679
Boglarka PosfaiDepartment of Pathology, Szeged University School of Medicine, Szeged, Hungary.ORCID http://orcid.org/0009-0000-0921-2235
Aysha MobeenDepartment of Pathology and Laboratory Medicine, University of New Mexico, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0002-7309-3397
Sambit K MohantyCore Diagnostics, Gurgaon, India.
Xulang ZhangDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.ORCID http://orcid.org/0009-0004-2970-3022
Mohammed A AlghamdiDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.ORCID http://orcid.org/0000-0002-8723-0858
Liang ChengDepartment of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, and Brown University Health, Providence, RI, USA.ORCID http://orcid.org/0000-0001-6049-5293
Michelle S HirschDepartment of Pathology and Laboratory Medicine, Brigham and Women's Hospital, 75 Francis St, Room AL.360E, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-8767-8564
Mahmut AkgulDepartment of Pathology and Laboratory Medicine, Brigham and Women's Hospital, 75 Francis St, Room AL.360E, Boston, MA, 02115, USA. makgul@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-0929-0940

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Succinate dehydrogenase deficient renal cell carcinoma (SDH RCC) is an uncommon, familial RCC that has overlapping morphologic features with other low grade eosinophilic tumors of the kidney. Although the diagnosis of SDH RCC relies on loss of SDHB by immunohistochemistry (IHC), not all laboratories have access to this antibody. GATA3 and L1CAM are increasingly utilized in the diagnosis of eosinophilic renal tumors; however, their expression profile has not been studied in SDH RCC. We evaluated clinical parameters and GATA3 and L1CAM reactivity in a large nephrectomy cohort (n = 40) of patients with SDH RCC. The male-to-female ratio was 3:1 and the median age was 48 years (range: 17 to 79 years). Specimens included 20 radical resections, 19 partial resections, and 1 unknown procedure. Tumor laterality was nearly equal (right:left = 18:20; one case was bilateral). Tumors in 4 (10%) patients were multifocal. Median tumor size was 2.0 cm (range 1 - 14.8 cm). Tumor stage distribution was: pT1a (n = 16, 40%), pT1b (n = 7, 18%), pT2a (n = 5, 13%), pT2b (n = 4, 10%), pT3a (n = 6, 15%), and pT4 (n = 1, 3%). Most cases (n = 33, 83%) exhibited classical morphologic features, whereas 2/40 (5%) had sarcomatoid differentiation. GATA3 was positive in 37/39 (95%) tumors, with more than 50% of cells positive in 35/37 (95%), and with moderate-high intensity (2/3 +) in 33/37 (89%). L1CAM was expressed in 13/18 (72%) tumors, with moderate-high intensity (2/3 +) in 10/13 (77%). When both markers were performed, dual GATA3/L1CAM expression was present in 12/17 (71%) tumors. As L1CAM has been postulated to represent a marker of principal cell of the distal nephron, frequent L1CAM expression in SDH RCC suggests that they may originate from the principal cells of the distal nephron.

Indexed as

Carcinoma, Renal CellGATA3 Transcription FactorNeural Cell Adhesion Molecule L1Succinate DehydrogenaseAdolescentAdultAgedBiomarkers, TumorFemaleHumansImmunohistochemistryMaleMiddle AgedTranscriptomeYoung AdultBiomarkers, TumorGATA3 protein, humanGATA3 Transcription FactorL1CAM protein, humanNeural Cell Adhesion Molecule L1Succinate DehydrogenaseGATA3L1CAMSuccinate dehydrogenase deficient renal cell carcinoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.